Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with < em > Staphylococcus Aureus < /em > by pharmacokinetic/pharmacodynamic analysis
J Chemother. 2024 Apr 22:1-8. doi: 10.1080/1120009X.2024.2343963. Online ahead of print.ABSTRACTOmadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concent...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Gaoqi Xu Xin Liu Jiaqi Wang Yuqing Mei Dihong Yang Chaoneng He Like Zhong Junfeng Zhu Haiying Ding Luo Fang Source Type: research
Etiology of bacterial pneumonia and multi-drug resistance pattern among pneumonia suspected patients in Ethiopia: a systematic review and meta-analysis
Bacterial pneumonia can affect all age groups, but people with weakened immune systems, young children, and the elderly are at a higher risk. Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus influenza... (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - April 16, 2024 Category: Respiratory Medicine Authors: Mihret Tilahun, Melaku Ashagrie Belete, Alemu Gedefie, Habtu Debash, Ermiyas Alemayehu, Daniel Gebretsadik, Hussein Ebrahim and Ousman Mohammed Tags: Research Source Type: research
Evaluating omadacycline dosing regimens against drug-resistant pathogens including < em > Staphylococcus aureus < /em > , < em > Streptococcus pneumoniae < /em > and < em > Haemophilus influenzae < /em > in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
In conclusion, approved oral/intravenous loading and maintenance doses of omadacycline showed enough efficacy in the treatment of ABSSI and CABP caused by the main drug-resistant pathogens.PMID:38591989 | DOI:10.1080/1120009X.2024.2339706 (Source: Journal of Chemotherapy)
Source: Journal of Chemotherapy - April 9, 2024 Category: Cancer & Oncology Authors: Xiao-Chen Wei Ming-Feng Zhao Xia Xiao Source Type: research
Comparative analysis of immunological biomarkers in COVID-19 and bacterial pneumonia
This study highlights the potential significant impact of COVID-19 on the immunological biomarkers investigated.PMID:38585537 | PMC:PMC10994609 | DOI:10.25122/jml-2023-0273 (Source: Journal of Medicine and Life)
Source: Journal of Medicine and Life - April 8, 2024 Category: General Medicine Authors: Mudathir Abdelshafea Abdelkareem Abakar Daralnaeem Hassan Ali Hamad Eman Faisal Hashim Mohamed Fad-Alla Omer Mahmoud Taha Mohamed Faki Abdellla Esmail Mohammed Idris Rouwida Omer Zeinab Osman Entesar Ahmed Gaffar Elhassan Mohamed Ahmed Abrahim-Holie Moham Source Type: research
Lung ultrasound and procalcitonin, improving antibiotic management and avoiding radiation exposure in pediatric critical patients with bacterial pneumonia: a randomized clinical trial
ConclusionsCombination of LUS and PCT showed no risk of mistreating BP, avoided radiation and did not increase costs. The algorithm could be a reliable tool for improving pneumonia management.Clinical Trial Registration: NCT04217980. (Source: European Journal of Medical Research)
Source: European Journal of Medical Research - April 6, 2024 Category: Research Source Type: research
